Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CLEC12A

CLEC12A

Brief Information

Name:C-Type lectin domain family 12 member A
Target Synonym:CD371 Antigen,C-Type Lectin-Like Molecule 1,MICL,CD371,CLEC12A,DCAL2,DCAL-2,Dendritic cell-associated lectin 2,C-Type Lectin Domain Family 12 Member A,Myeloid Inhibitory C-Type Lectin-Like Receptor,CLL-1,CLL1,C-Type Lectin Domain Family 12, Member A,C-Type Lectin-Like Molecule-1,C-Type Lectin Protein CLL-1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:20
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CLA-HA248-Cell-based assay
 CLEC12A FACS

5e5 of anti-CLEC12A / CLL-1 CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HA248) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).

CLA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-CLEC12A/CLL-1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CLEC12A, His Tag (Cat. No. CLA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CLA-H82E6-ELISA
 CLEC12A ELISA

Immobilized Biotinylated Human CLEC12A, His,Avitag (Cat. No. CLA-H82E6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Monoclonal Anti-Human CLEC12A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (QC tested).

CLA-H5266-MALS-HPLC
CLEC12A MALS images

The purity of Human CLEC12A, Fc Tag (Cat. No. CLA-H5266) is more than 90% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.

Synonym Name

CLEC12A,MICL,CLL-1,CLL1,DCAL2,DCAL-2,CD371

Background

CLEC12A (C-type lectin domain family 12 member A) is also known as CLL1, DCAL2, MICL. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Cell surface receptor that modulates signaling cascades and mediates tyrosine phosphorylation of target MAP kinases. Evidence of distinct disease propagating stem cells in myelodysplastic syndrome (MDS) has emerged in recent years.  The role of CLEC12A in MDS, however, remains to be elucidated. Furthermore, CLEC12A has been proposed as a promising marker of leukaemic stem cells in AML.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CLL1+CD33 CAR-T(Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CLL1 CAR-NK cell (Zhejiang University/Hangzhou Qihangene Biotech) Phase 1 Clinical Zhejiang University, Hangzhou Qihan Jiyin Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
KITE-222 Phase 1 Clinical Kite Pharma Leukemia, Myeloid, Acute Details
Anti-CD33/CLL1 CAR-NK Cell Therapy Phase 1 Clinical Imbioray (Hangzhou) Biomedicine Co Ltd Leukemia, Myeloid, Acute Details
CLL1 CAR-T(Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CLL1 CAR T-cell Therapy(Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Leukemia, Myeloid, Acute Details
IBR-733 IBR-733; IBR733 Phase 1 Clinical Imbioray (Hangzhou) Biomedicine Co Ltd Leukemia, Myeloid, Acute Details
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) Phase 1 Clinical Shenzhen Geno-Immune Medical Institute Leukemia, Myeloid, Acute Details
Tepoditamab MCLA-117 Phase 1 Clinical Pharmaceutical Research Associates, Institute Gustave-Roussy, Merus Nv, Vu University Medical Center, Lgc Leukemia, Myeloid, Acute Details
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) Phase 1 Clinical The 920th Hospital Of Joint Logistics Support Force Of PLA Leukemia, Myeloid, Acute Details
DCLL-9718S DCLL-9718S; MCLL-0517A; RG-6109 Phase 1 Clinical F. Hoffmann-La Roche Ltd Leukemia, Myeloid, Acute Details
ICG-136 ICG-136; 123b-33bcCAR Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Leukemia, Myeloid, Acute Details
Anti-CLL1 CAR T cell therapy(Soochow University) Phase 2 Clinical The First Affiliated Hospital Of Soochow University Leukemia, Myeloid, Acute Details
CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital) Phase 1 Clinical Hangzhou Qihan Biotechnology Co Ltd Neoplasm, Residual; Leukemia, Myeloid, Acute Details
CD371-YSNVZ-IL18 CAR T cells therapy Phase 1 Clinical Memorial Sloan Kettering Cancer Center Leukemia, Myeloid, Acute Details
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) Phase 3 Clinical Fujian Medical University Leukemia, Myeloid, Acute Details
Anti-CD33/CLL-1 CAR-T (Legend) Phase 1 Clinical Legend Biotech Corp Leukemia, Promyelocytic, Acute Details
CLL-1.CAR T cell therapy (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Leukemia, Myeloid, Acute Details
Anti-CLL1 CAR-T (Guangzhou Bio-Gene) BG-1805; BG1805 Phase 2 Clinical Guangzhou Bio-Gene Technology Co Ltd Leukemia, Myeloid, Acute Details
CLL-1/CD33 Targeted LCAR-AMDR Cells(Nanjing Legend Biotechnology) Phase 1 Clinical Nanjing Legend Biotechnology Co Ltd Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message